Shapes of the trajectories of 5 major biomarkers of Alzheimer disease

Archives of Neurology

Volumn 69, Issue 7, 2012, Pages 856-867

  Jack, Clifford R ^a   Vemuri, Prashanthi ^a   Wiste, Heather J ^a   Weigand, Stephen D ^a   Lesnick, Timothy G ^a   Lowe, Val ^a   Kantarci, Kejal ^a   Bernstein, Matt A ^a   Senjem, Matthew L ^a   Gunter, Jeffrey L ^a   Boeve, Bradley F ^a   Trojanowski, John Q ^b   Shaw, Leslie M ^b   Aisen, Paul S ^c   Weiner, Michael W ^d   Petersen, Ronald C ^a   Knopman, David S ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; FLUORODEOXYGLUCOSE; TAU PROTEIN;

AGE DISTRIBUTION; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN LEVEL; BRAIN SIZE; CEREBROSPINAL FLUID ANALYSIS; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HIPPOCAMPUS; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RELIABILITY; STRUCTURAL MAGNETIC RESONANCE IMAGING;

EID: 84863800101     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2011.3405     Document Type: Article

References (66)

1. Peskind ER, Li G, Shofer J, et al. Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition. Arch Neurol. 2006;63(7):936-939. (Pubitemid 44036292)
2. Bouwman FH, Schoonenboom NS, Verwey NA, et al. CSF biomarker levels in early and late onset Alzheimer's disease. Neurobiol Aging. 2009;30(12):1895- 1901.
3. Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007;64(3):343-349. (Pubitemid 46425688)
4. Fagan AM, Head D, Shah AR, et al. Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol. 2009;65(2):176-183.
5. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al Alzheimer's Disease Neuroimaging Initiative. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol. 2009;65(4):403-413.
6. Li G, Sokal I, Quinn JF, et al. CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology. 2007;69(7):631-639. (Pubitemid 47256004)
7. Mattsson N, Zetterberg H, Hansson O, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA. 2009;302(4):385-393.
8. Visser PJ, Verhey F, Knol DL, et al. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol. 2009;8(7):619-627.
9. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306-319. (Pubitemid 38269583)
10. Mintun MA, Larossa GN, Sheline YI, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67(3):446-452. (Pubitemid 44214969)
11. Rowe CC, Ellis KA, Rimajova M, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010;31(8):1275-1283.
12. Rowe CC, Ng S, Ackermann U, et al. Imaging beta-amyloid burden in aging and dementia. Neurology. 2007;68(20):1718-1725. (Pubitemid 46763260)
13. Pike KE, Ellis KA, Villemagne VL, et al. Cognition and beta-amyloid in preclinical Alzheimer's disease: data from the AIBL study. Neuropsychologia. 2011;49(9):2384-2390.
14. Villemagne VL, Pike KE, Chételat G, et al. Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann Neurol. 2011;69(1):181-192.
15. Rabinovici GD, Furst AJ, O'Neil JP, et al. 11C-PiB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology. 2007;68(15):1205-1212. (Pubitemid 46608468)
16. Hampel H, Frank R, Broich K, et al. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov. 2010;9(7):560-574.
17. Blennow K. Biomarkers in Alzheimer's disease drug development. Nat Med. 2010;16(11):1218-1222.
18. Glodzik L, de Santi S, Tsui WH, et al. Phosphorylated tau 231, memory decline and medial temporal atrophy in normal elders. Neurobiol Aging. 2011;32(12):2131-2141.
19. Jagust WJ, Bandy D, Chen K, et al; Alzheimer's Disease Neuroimaging Initiative. The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement. 2010;6(3):221-229.
20. Lowe VJ, Kemp BJ, Jack CR Jr, et al. Comparison of 18F-FDG and PiB PET in cognitive impairment. J Nucl Med. 2009;50(6):878-886.
21. Dickerson BC, Stoub TR, Shah RC, et al. Alzheimer-signature MRI biomarker predicts AD dementia in cognitively normal adults. Neurology. 2011;76(16):1395-1402.
22. Vemuri P, Whitwell JL, Kantarci K, et al. Antemortem MRI based STructural Abnormality iNDex (STAND)-scores correlate with postmortem Braak neurofibrillary tangle stage. Neuroimage. 2008;42(2):559-567.
23. Becker JA, Hedden T, Carmasin J, et al. Amyloid-β associated cortical thinning in clinically normal elderly. Ann Neurol. 2011;69(6):1032- 1042.
24. Jack CR Jr, Wiste HJ, Vemuri P, et al Alzheimer's Disease Neuroimaging Initiative. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain. 2010;133(11):3336-3348.
25. Desikan RS, Cabral HJ, Hess CP, et al Alzheimer's Disease Neuroimaging Initiative. Automated MRI measures identify individuals with mild cognitive impairment and Alzheimer's disease. Brain. 2009;132(pt 8):2048-2057.
26. Hua X, Leow AD, Parikshak N, et al Alzheimer's Disease Neuroimaging Initiative. Tensor-based morphometry as a neuroimaging biomarker for Alzheimer's disease: an MRI study of 676 AD, MCI, and normal subjects. Neuroimage. 2008;43(3):458-469.
27. Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010;9(1):119-128.
28. Ingelsson M, Fukumoto H, Newell KL, et al. Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology. 2004;62(6):925-931. (Pubitemid 38435780)
29. Mormino EC, Kluth JT, Madison CM, et al Alzheimer's Disease Neuroimaging Initiative. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain. 2009;132(pt 5):1310-1323.
30. Perrin RJ, Fagan AM, Holtzman DM. Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature. 2009;461(7266):916-922.
31. Jack CR Jr, Lowe VJ, Weigand SD, et al Alzheimer's Disease Neuroimaging Initiative. Serial PiB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain. 2009;132(pt 5):1355-1365.
32. Villain N, Fouquet M, Baron JC, et al. Sequential relationships between grey matter and white matter atrophy and brain metabolic abnormalities in early Alzheimer's disease. Brain. 2010;133(11):3301-3314.
33. Jack CR Jr, Vemuri P, Wiste HJ, et al Alzheimer's Disease Neuroimaging Initiative. Evidence for ordering of Alzheimer disease biomarkers. Arch Neurol. 2011;68(12):1526-1535.
34. Roberts RO, Geda YE, Knopman DS, et al. The Mayo Clinic Study of Aging: design and sampling, participation, baselinemeasures and sample characteristics. Neuroepidemiology. 2008;30(1):58-69. (Pubitemid 351311727)
35. Petersen RC, Roberts RO, Knopman DS, et al. Mild cognitive impairment: ten years later. Arch Neurol. 2009;66(12):1447-1455.
36. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198.
37. Kokmen E, Smith GE, Petersen RC, Tangalos E, Ivnik RC. The Short Test of Mental Status: correlations with standardized psychometric testing. Arch Neurol. 1991;48(7):725-728.
38. Tang-Wai DF, Knopman DS, Geda YE, et al. Comparison of the short test of mental status and the Mini-Mental State Examination in mild cognitive impairment. Arch Neurol. 2003;60(12):1777-1781. (Pubitemid 37521636)
39. Vanderstichele H, De Meyer G, Shapiro F, et al. Biomarkers For Early Diagnosis of Alzheimer's Disease. Hauppauge, NY: Nova Science Publishers, Inc; 2008.
40. Jack CR Jr, Bernstein MA, Fox NC, et al. The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging. 2008;27(4):685-691. (Pubitemid 351508080)
41. Fischl B, Salat DH, Busa E, et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron. 2002;33(3):341-355. (Pubitemid 34162530)
42. Gunter JL, Bernstein MA, Borowski BJ, et al. Measurement of MRI scanner performance with the ADNI phantom. Med Phys. 2009;36(6):2193-2205.
43. Lin LI. A concordance correlation coefficient to evaluate reproducibility. Biometrics. 1989;45(1):255-268.
44. Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem. 2003;46(13):2740-2754. (Pubitemid 36702542)
45. Jack CR Jr, Lowe VJ, Senjem ML, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain. 2008;131(pt 3):665-680. (Pubitemid 351294719)
46. Price JC, Klunk WE, Lopresti BJ, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab. 2005;25(11):1528-1547. (Pubitemid 41541962)
47. McNamee RL, Yee SH, Price JC, et al. Consideration of optimal time window for Pittsburgh compound B PET summed uptakemeasurements. J Nucl Med. 2009;50(3):348-355.
48. Landau SM, Harvey D, Madison CM, et al Alzheimer's Disease Neuroimaging Initiative. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology. 2010;75(3):230-238.
49. Fitzmaurice GM, Laird NM, Ware JH. Applied Longitudinal Analysis. Hoboken, NJ: Wiley-Interscience; 2004.
50. Caselli RJ, Dueck AC, Osborne D, et al. Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. N Engl J Med. 2009;361(3):255-263.
51. Weigand SD, Vemuri P, Wiste HJ, et al Alzheimer's Disease Neuroimaging Initiative. Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh Compound B units of brain Aβ amyloid. Alzheimers Dement. 2011;7(2):133-141.
52. Vemuri P, Wiste HJ, Weigand SD, et al Alzheimer's Disease Neuroimaging Initiative. Serial MRI and CSF biomarkers in normal aging, MCI, and AD. Neurology. 2010;75(2):143-151.
53. Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci. 2001;21(2):372-381. (Pubitemid 32107428)
54. Crowe A, Ballatore C, Hyde E, Trojanowski JQ, Lee VM. High throughput screening for small molecule inhibitors of heparin-induced tau fibril formation. Biochem Biophys Res Commun. 2007;358(1):1-6. (Pubitemid 46719073)
55. Lomasko T, Lumsden CJ. One-hit stochastic decline in amechanochemical model of cytoskeleton-induced neuron death III: diffusion pulse death zones. J Theor Biol. 2009;256(1):104-116.
56. Clarke G, Lumsden CJ. Heterogeneous cellular environments modulate one-hit neuronal death kinetics. Brain Res Bull. 2005;65(1):59-67. (Pubitemid 40186931)
57. Caroli A, Frisoni GB; Alzheimer's Disease Neuroimaging Initiative. The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort. Neurobiol Aging. 2010;31(8):1263-1274.
58. Lo RY, Hubbard AE, Shaw LM, et al Alzheimer's Disease Neuroimaging Initiative. Longitudinal change of biomarkers in cognitive decline. Arch Neurol. 2011;68(10):1257-1266.
59. Schuff N, Woerner N, Boreta L, et al Alzheimer's Disease Neuroimaging Initiative. MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. Brain. 2009;132(pt 4):1067-1077.
60. Sabuncu MR, Desikan RS, Sepulcre J, et al Alzheimer's Disease Neuroimaging Initiative. The dynamics of cortical and hippocampal atrophy in Alzheimer disease. Arch Neurol. 2011;68(8):1040-1048.
61. Mungas D, Reed BR, Kramer JH. Psychometrically matched measures of global cognition, memory, and executive function for assessment of cognitive decline in older persons. Neuropsychology. 2003;17(3):380-392. (Pubitemid 37013149)
62. Chan D, Janssen JC, Whitwell JL, et al. Change in rates of cerebral atrophy over time in early-onset Alzheimer's disease: longitudinal MRI study. Lancet. 2003;362(9390):1121-1122. (Pubitemid 37222338)
63. Ridha BH, Barnes J, Bartlett JW, et al. Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study. Lancet Neurol. 2006;5(10):828-834. (Pubitemid 44715810)
64. Carlson NE, Moore MM, Dame A, et al. Trajectories of brain loss in aging and the development of cognitive impairment. Neurology. 2008;70(11):828-833. (Pubitemid 351367518)
65. Jack CR Jr, Weigand SD, Shiung MM, et al. Atrophy rates accelerate in amnestic mild cognitive impairment. Neurology. 2008;70(19, pt 2):1740-1752. (Pubitemid 351653966)
66. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging and the Alzheimer Association Workgroup. Alzheimers Dement. 2011:1-13. doi:10.1016/j.jalz.2011.03.003.